Holen Sie sich die Stockscreener-App
316.58
4.07%
-13.42
Schlusskurs vom Vortag:
$330.00
Offen:
$329.94
24-Stunden-Volumen:
226.11K
Relative Volume:
0.82
Marktkapitalisierung:
$9.37B
Einnahmen:
$417.30M
Nettoeinkommen (Verlust:
$225.03M
KGV:
42.32
EPS:
7.4815
Netto-Cashflow:
$237.38M
1W Leistung:
-4.53%
1M Leistung:
-5.97%
6M Leistung:
+19.89%
1J Leistung:
+68.10%
1-Tages-Spanne:
$315.38
$331.02
1-Wochen-Bereich:
$315.38
$338.91
52-Wochen-Spanne:
$183.03
$382.54
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
316.58 | 9.37B | 417.30M | 225.03M | 237.38M | 7.4815 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-24 | Fortgesetzt | Goldman | Buy |
| 2026-08-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-03-27 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome - Zacks Investment Research
Why Krystal Biotech (KRYS) Is Drawing Fresh Attention - Yahoo Finance
Krystal Biotech (NASDAQ: KRYS) Grants Director Sutherland Everett Rand 1,658 Derivative Securities - Kalkine Media
Krystal Biotech (NASDAQ: KRYS) Grants Director Janney Daniel 1,658 Derivative Securities at Zero Cost - Kalkine Media
Krystal Biotech (NASDAQ: KRYS) Grants 1,658 Derivative Securities to Director Catherine Mazzacco - Kalkine Media
Krystal Biotech (NASDAQ: KRYS) Grants 1,658 Derivative Securities to Director Mason Christopher - Kalkine Media
Director at Krystal Biotech (KRYS) gets new stock options and RSUs - Stock Titan
Krystal Biotech (KRYS) board member receives new options and RSUs - Stock Titan
(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
What Put Krystal Biotech (KRYS) in Focus? - Kalkine Media
Krystal Biotech at Cantor healthcare conference: pipeline gains pace By Investing.com - Investing.com Canada
KRYS: International expansion and pipeline progress set the stage for multi-product growth - TradingView
Krystal Biotech at Cantor healthcare conference: pipeline gains pace - Investing.com
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Krystal Biotech CEO Krishnan Krish S Sells 25,000 Shares at Prices Up to $366.56 on September 4, 2026 - Kalkine Media
Krystal Biotech President Krishnan Suma Disposes of 25,000 Shares at $354.54-$366.56 (NASDAQ: KRYS) - Kalkine Media
Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing - Yahoo Finance
Top insider buys and sells disclosed for Friday - Investing.com
Krystal Biotech, Inc. (KRYS) Stock Analysis: Unveiling a 7.47% Potential Upside with Promising Genetic Medicine Innovations - DirectorsTalk Interviews
Top insider buys and sells disclosed for Friday By Investing.com - Investing.com Nigeria
Top insider buys and sells disclosed for Friday By Investing.com - Investing.com India
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock By Investing.com - Investing.com South Africa
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock By Investing.com - Investing.com Australia
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com Nigeria
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock - Investing.com Nigeria
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock - Investing.com
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock By Investing.com - Investing.com South Africa
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com India
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock - Moomoo
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock - Moomoo
Krystal Biotech (KRYS) R&D head sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) CEO sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) holder to sell 25,000 founders shares - Stock Titan
Krystal Biotech (KRYS) insider moves to sell 2017 shares in a multimillion-dollar deal - Stock Titan
Krystal Biotech stock steadies as regulatory debate over Vyjuvek intensifies - ad-hoc-news.de
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? - TradingView
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? - Zacks Investment Research
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference - The Manila Times
Krystal Biotech to Participate in 2026 Cantor Global Healthcare Conference - Quiver Quantitative
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference - marketscreener.com
A healthcare conference webcast is set for Sept. 10 in New York - Stock Titan
Krystal Biotech stock gains on solid Q2 2026 Vyjuvek growth - ad-hoc-news.de
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings And 9.54% Potential Upside - DirectorsTalk Interviews
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Krystal Biotech, Inc. (KRYS) Stock Analysis: Discovering a 11% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Krystal Biotech Inc-Aktie (KRYS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SUMA KRISHNAN | Director |
Sep 04 '26 |
Proposed Sale |
371.47 |
25,000 |
9,286,750 |
0 |
| Krishnan Krish S | President and CEO |
Sep 04 '26 |
Sale |
359.32 |
25,000 |
8,983,084 |
1,347,543 |
| KRISH KRISHNAN | Director |
Sep 04 '26 |
Proposed Sale |
371.47 |
25,000 |
9,286,750 |
0 |
| Dino A. Rossi | Director |
Aug 14 '26 |
Proposed Sale |
332.27 |
25,000 |
8,306,750 |
0 |
| ROSSI DINO A | Director |
Aug 14 '26 |
Sale |
329.12 |
25,000 |
8,227,953 |
50,000 |
| Thomas John Charles | EVP, General Counsel |
Jun 25 '26 |
Option Exercise |
179.25 |
1,000 |
179,250 |
1,000 |
| Thomas John Charles | Officer |
Jun 25 '26 |
Proposed Sale |
347.27 |
1,000 |
347,270 |
0 |
| Thomas John Charles | EVP, General Counsel |
Jun 25 '26 |
Sale |
347.27 |
1,000 |
347,270 |
0 |
| Krishnan Suma | President, R&D |
Jun 04 '26 |
Sale |
308.11 |
25,000 |
7,702,825 |
1,378,155 |
| Krishnan Krish S | President and CEO |
Jun 04 '26 |
Sale |
308.12 |
25,000 |
7,702,984 |
1,450,253 |
8.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):